Staff

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™

Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 20211 Biologics License Application accepted by...

error: Content is protected !!